Skip to main content

Table 4 Most frequent AEs (at least three patients in either treatment group) and discontinuations due to AEs (safety set), n (%)

From: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Preferred term Glycopyrronium 50 μg o.d. (N = 327) n (%) Tiotropium 18 μg o.d. (N = 330) n (%)
Any AE 132 (40.4) 134 (40.6)
   COPD worsening 50 (15.3) 58 (17.6)
   Nasopharyngitis 14 (4.3) 8 (2.4)
   Headache 12 (3.7) 7 (2.1)
   Bacterial upper respiratory tract infection 10 (3.1) 11 (3.3)
   Upper respiratory tract infection 9 (2.8) 5 (1.5)
   Cough 5 (1.5) 5 (1.5)
   Viral upper respiratory tract infection 5 (1.5) 6 (1.8)
   Urinary tract infection 4 (1.2) 1 (0.3)
   Lower respiratory tract infection 3 (0.9) 3 (0.9)
   Influenza 2 (0.6) 4 (1.2)
   Non-cardiac chest pain 2 (0.6) 3 (0.9)
   Pneumonia 2 (0.6) 3 (0.9)
   Arthralgia 1 (0.3) 5 (1.5)
   Dry mouth 1 ( 0.3) 5 (1.5)
   Odema peripheral 1 ( 0.3) 5 (1.5)
   Blood glucose increased 0 3 (0.9)
   Gastritis 0 3 (0.9)
   Renal failure acute 0 3 (0.9)
   Sinusitis 0 3 (0.9)
Discontinuation due to AE(s) 7 (2.1) 5 (1.5)
  1. AE = adverse event; o.d. = once daily.